{
  "meta": {
    "title": "Drug_Metabolism_And_Toxicity",
    "url": "https://brainandscalpel.vercel.app/drug-metabolism-and-toxicity-130f5e81.html",
    "scrapedAt": "2025-12-01T04:08:19.770Z"
  },
  "questions": [
    {
      "text": "<p>A 68-year-old woman comes to the office due to a burning sensation in her chest and throat for the past 2 weeks.&nbsp; Associated symptoms include trouble swallowing.&nbsp; Medical history is significant for osteoporosis, and she has no known drug allergies.&nbsp; The patient has smoked half a pack of cigarettes daily for 50 years, and does not use alcohol or illicit drugs.&nbsp; Temperature is 36.7 C (98 F), blood pressure is 110/70 mm Hg, and pulse is 70/min.&nbsp; BMI is 20 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Cardiopulmonary examination shows clear lungs and normal S1 and S2.&nbsp; The abdomen is soft and nontender.&nbsp; Laboratory results are normal.&nbsp; It is determined that the patient&#39;s current symptoms are caused by one of her medications, which is discontinued.&nbsp; Her symptoms subsequently resolve.&nbsp; The medication responsible for this patient&#39;s presentation is also associated with which of the following side effects?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Chronic kidney disease"
        },
        {
          "id": 2,
          "text": "Hypercalcemia"
        },
        {
          "id": 3,
          "text": "Osteonecrosis of the jaw"
        },
        {
          "id": 4,
          "text": "Venous thromboembolism"
        },
        {
          "id": 5,
          "text": "Vitamin B12 deficiency"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Osteoporosis</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t39238\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Medication-induced esophagitis </strong></p></td></tr><tr><td><p align=\"center\"><strong>Drug class </strong></p></td><td><p align=\"center\"><strong>Drug </strong></p></td></tr><tr><td><p align=\"center\">Antibiotics</p></td><td><p>Tetracyclines</p></td></tr><tr><td><p align=\"center\">Anti-inflammatory agents</p></td><td><p>Aspirin &amp; many nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td><p align=\"center\">Bisphosphonates</p></td><td><p>Alendronate, risedronate</p></td></tr><tr><td><p align=\"center\">Others</p></td><td><p>Potassium chloride, iron</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient has esophagitis, with burning pain in the chest and dysphagia.&nbsp; <strong>Medication-induced esophagitis</strong> is a common adverse effect of <strong>bisphosphonates</strong> (eg, alendronate, risedronate) thought to be caused by disruption of the protective phospholipid barrier in the lower esophagus.&nbsp; This allows refluxing gastric acid to cause mucosal erosion and ulceration.&nbsp; Bisphosphonates are contraindicated in conditions that impair esophageal motility (eg, stricture, achalasia).&nbsp; When bisphosphonates are used, the risk of esophagitis can be lessened by taking the medication with a full glass of water (to ensure the pill is delivered fully into the stomach) and remaining upright for 30 minutes following administration (to avoid reflux of gastric contents).</p><p>Bisphosphonates are also associated with <strong>osteonecrosis of the jaw</strong> (mandible or maxilla) and atypical bone fractures (eg, stress fractures of the subtrochanteric zone and femoral shaft).&nbsp; The precise pathophysiology is debated and may vary, but proposed mechanisms include suppression of bone remodeling, impaired healing of microfractures, and decreased angiogenesis.</p><p><strong>(Choice A)</strong>&nbsp; Medication-induced nephropathy can be due to interstitial nephritis (eg, cyclosporine), crystal nephropathy (eg, acyclovir), renal vasoconstriction (eg, amphotericin B, nonsteroidal anti-inflammatory drugs), or tubular injury (eg, aminoglycosides).&nbsp; Bisphosphonates are eliminated by the kidney and should be used with caution in patients with chronic kidney disease, but do not have substantial nephrotoxicity.</p><p><strong>(Choice B)</strong>&nbsp; Bisphosphonates decrease bone resorption, thus lowering serum calcium levels.&nbsp; They are sometimes used in the treatment of severe hypercalcemia (eg, hypercalcemia of malignancy).</p><p><strong>(Choice D)</strong>&nbsp; Venous thromboembolism is a recognized complication of selective estrogen receptor modulators (eg, raloxifene), but these medications do not often cause esophagitis.&nbsp; Bisphosphonates do not appreciably increase the risk of thromboembolism.</p><p><strong>(Choice E)</strong>&nbsp; Vitamin B<font size=\"2\"><sub>12</sub></font> deficiency can be seen in long-term proton pump inhibitor (eg, omeprazole) therapy, possibly due to decreased acid-dependent cleavage of vitamin B<font size=\"2\"><sub>12</sub></font> from dietary proteins.&nbsp; Although proton pump inhibitors may be taken by patients with bisphosphonate-induced esophagitis, bisphosphonates do not affect vitamin B<font size=\"2\"><sub>12</sub></font> metabolism.</p><p><strong>Educational objective:</strong><br>Medication-induced esophagitis is a common adverse effect of bisphosphonates.&nbsp; Bisphosphonates are also associated with increased risk of osteonecrosis of the jaw and atypical femoral fractures.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "13535",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 47-year-old man comes to the office due to worsening muscle weakness and dark urine for the past several days.&nbsp; Two weeks ago, the patient was evaluated for dyspepsia and found to have <em>Helicobacter pylori</em> infection; he was started on treatment and has had partial symptom improvement.&nbsp; Medical history includes hypertension and hyperlipidemia, for which he takes amlodipine and simvastatin.&nbsp; Temperature is 37.1 C (98.8 F), blood pressure is 130/80 mm Hg, and pulse is 74/min.&nbsp; Physical examination shows diffuse muscle tenderness.&nbsp; Laboratory evaluation reveals elevated blood urea nitrogen and serum creatinine levels.&nbsp; Urine microscopy shows no red or white blood cells.&nbsp; Which of the following medications most likely precipitated this patient&#39;s current condition?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Amoxicillin"
        },
        {
          "id": 2,
          "text": "Bismuth subsalicylate"
        },
        {
          "id": 3,
          "text": "Calcium carbonate"
        },
        {
          "id": 4,
          "text": "Clarithromycin"
        },
        {
          "id": 5,
          "text": "Metronidazole"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Drug induced myopathy</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t57182\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Concurrent medications &amp; statin myopathy</strong></p></td></tr><tr><td><p align=\"center\"><strong>Cytochrome P-450<br />(CYP3A4) inhibitors</strong></p></td><td><ul><li>Nondihydropyridine CCBs (eg,&nbsp;verapamil, diltiazem)</li><li>Protease inhibitors (eg,&nbsp;ritonavir, saquinavir)</li><li>Erythromycin</li></ul></td></tr><tr><td><p align=\"center\"><strong>OATP inhibitors</strong></p></td><td><ul><li>Cyclosporine (also a CYP3A4 inhibitor)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Additive myocyte toxicity</strong></p></td><td><ul><li>Corticosteroids</li><li>Fibrates (eg,&nbsp;gemfibrozil)</li><li>Colchicine (also competes with statins for CYP3A4 metabolism)</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>CCBs</strong> = calcium channel blockers; <strong>OATP</strong> = organic anion transport protein.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient has muscle tenderness and weakness.&nbsp; The dark urine suggests <strong>myoglobinuria </strong>due to myocyte necrosis.&nbsp; In the context of ongoing statin therapy for hyperlipidemia, this presentation likely represents statin myopathy.&nbsp; Statin myopathy is due, likely at least in part, to decreased myocyte production of coenzyme Q10 (ubiquinone).&nbsp; Serum muscle breakdown markers (eg, creatine kinase) are often elevated, and severe cases may lead to <strong>rhabdomyolysis </strong>with subsequent <strong>acute kidney injury</strong> (eg, elevated BUN and creatinine).</p><p><strong>Statin myopathy</strong> is most common in the initial weeks or months of therapy.&nbsp; However, it can occasionally occur later, and can be acutely triggered by medications that increase circulating statin levels.&nbsp; This patient&#39;s myopathy is most likely related to the initiation of clarithromycin as part of a multidrug regimen for <em>Helicobacter pylori</em>.</p><p>Statins, primarily simvastatin, lovastatin, and atorvastatin, are metabolized by <strong>CYP3A4</strong>.&nbsp; This enzyme can be <strong>inhibited by macrolide antibiotics</strong> (eg, erythromycin, clarithromycin), leading to increased statin drug levels and subsequent statin myopathy.&nbsp; (Azithromycin does not significantly inhibit CYP3A4.)&nbsp; Other significant CYP3A4 inhibitors that can induce statin myopathy include ketoconazole, non&ndash;dihydropyridine calcium channel blockers (eg, diltiazem), amiodarone, and protease inhibitors (eg, ritonavir).&nbsp; Because pravastatin is not primarily metabolized by CYP3A4, patients who must take a CYP3A4 inhibitor may benefit from switching to this drug.</p><p><strong>(Choice A)</strong>&nbsp; Amoxicillin does not inhibit CYP3A4 or increase circulating simvastatin levels.&nbsp; Penicillin antibiotics generally have only minor effects on the cytochrome P-450 system.</p><p><strong>(Choice B)</strong>&nbsp; Bismuth subsalicylate can cause black stools due to the formation of bismuth sulfate in the gastrointestinal tract.&nbsp; However, this medication does not cause myopathy or myoglobinuria.&nbsp; Excessive intake of bismuth can cause motor weakness, but this is due primarily to neural rather than muscle toxicity.</p><p><strong>(Choice C)</strong>&nbsp; Polyvalent cations (eg, calcium, iron) can form insoluble chelate complexes with certain antibiotics (eg, tetracyclines, fluoroquinolones) and other drugs (eg, levothyroxine, levodopa), leading to decreased drug absorption.&nbsp; Simvastatin does not form chelate complexes, and decreased absorption would lower, not increase, the risk for myopathy.</p><p><strong>(Choice E)</strong>&nbsp; Both metronidazole and simvastatin carry a small risk for peripheral neuropathy.&nbsp; In some patients, the effect can be additive and lead to numbness, pain, and paresthesia in the hands and feet.&nbsp; However, this neuropathy would not cause muscle tenderness or myoglobinuria.</p><p><strong>Educational objective:</strong><br>Statins, primarily simvastatin, lovastatin, and atorvastatin, are metabolized by CYP3A4.&nbsp; Drugs that inhibit this enzyme (eg, macrolide antibiotics, ketoconazole, non&ndash;dihydropyridine calcium channel blockers, amiodarone) can cause increased statin drug levels and lead to statin myopathy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "161",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 64-year-old woman comes to the hospital due to sudden-onset right arm weakness and difficulty speaking, which completely resolved within 20 minutes.&nbsp; The patient has had no shaking movements, headache, nausea, photophobia, or anxiety.&nbsp; She has a history of hypertension and hypercholesterolemia and takes amlodipine and rosuvastatin, respectively.&nbsp; Her blood pressure is 125/70 mm Hg and pulse is 78/min and regular.&nbsp; Neurologic examination is unremarkable.&nbsp; Fingerstick glucose is within normal limits.&nbsp; ECG shows normal sinus rhythm.&nbsp; Carotid Doppler reveals mild left common carotid artery stenosis.&nbsp; MRI of the brain and echocardiogram are unremarkable.&nbsp; If the patient is started on an additional medication that is indicated for her condition, which of the following adverse effects is most likely to occur?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Central nervous system depression"
        },
        {
          "id": 2,
          "text": "Gastrointestinal bleeding"
        },
        {
          "id": 3,
          "text": "Hyperpnea and vertigo"
        },
        {
          "id": 4,
          "text": "Orthostatic hypotension"
        },
        {
          "id": 5,
          "text": "Sexual dysfunction"
        },
        {
          "id": 6,
          "text": "Urinary bladder cancer"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Antiplatelet therapy</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img  draggable=\"false\" id=\"6705\" src=\"https://www.uworld.com/media/L25950.jpg\"  ></p><p>This patient, with hypertension, hypercholesterolemia, and sudden-onset neurologic deficits (eg, right arm weakness, difficulty speaking) that fully resolved within minutes, most likely had a <strong>transient ischemic attack</strong> (TIA).&nbsp; In addition to optimal blood pressure control and statin therapy, <strong>low-dose aspirin</strong> is commonly used to <strong>prevent ischemic stroke</strong> in patients with TIA.&nbsp; It works by irreversibly acetylating/inhibiting the cyclooxygenase (COX) enzymes.&nbsp; At low doses, aspirin predominantly <strong>inhibits COX-1</strong>, preventing platelet synthesis of thromboxane A2, which <strong>impairs platelet aggregation</strong> and reduces vasoconstriction.</p><p>At least 2 distinct COX-1-dependent mechanisms contribute to the increased risk of upper <strong>gastrointestinal (GI) bleeding</strong> associated with aspirin therapy: Inhibition of platelet aggregation and impairment of prostaglandin-dependent GI mucosal protection.&nbsp; The risk of upper GI bleeding increases with higher doses but is increased 2- to 3-fold even with low-dose aspirin.&nbsp; Proton pump inhibitors can help reduce the risk of upper GI bleeding in patients taking aspirin.</p><p><strong>(Choice A)</strong>&nbsp; Central nervous system depression is commonly seen with benzodiazepine use as these agents potentiate the effect of GABA (a major inhibitory neurotransmitter) on GABA-A receptors.</p><p><strong>(Choice C)</strong>&nbsp; Very high doses of aspirin can cause salicylism (eg, vertigo, tinnitus, hearing loss) and hyperpnea (stimulates respiratory drive).&nbsp; Hyperpnea may result in respiratory alkalosis, whereas systemic salicylate accumulation often leads to a concurrent metabolic acidosis.</p><p><strong>(Choice D)</strong>&nbsp; Orthostatic hypotension may occur with use of antihypertensive medications due to vasodilation (eg, nitrates, calcium channel blockers) and volume depletion (eg, loop and thiazide diuretics).</p><p><strong>(Choice E)</strong>&nbsp; Sexual dysfunction is a common side effect of antidepressants (eg, selective serotonin reuptake inhibitors, tricyclics) and some antihypertensives (eg, thiazide diuretics, spironolactone, clonidine).</p><p><strong>(Choice F)</strong>&nbsp; Pioglitazone (a thiazolidinedione) increases insulin sensitivity in patients with type II diabetes mellitus by binding to peroxisome proliferator-activated receptors.&nbsp; Long-term use may be associated with urinary bladder cancer.</p><p><strong>Educational objective:</strong><br>Gastrointestinal (GI) mucosal injury and bleeding are the most common side effects of aspirin.&nbsp; These are due primarily to cyclooxygenase-1 inhibition, which results in impaired prostaglandin-dependent GI mucosal defense and decreased platelet aggregation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "713",
      "difficulty": "N/A"
    },
    {
      "text": "<P>A group of investigators is performing an experiment designed to assess genetic variability in drug biotransformation.&nbsp; A fixed dose of isoniazid is given to a group of volunteers, and the plasma drug concentration is measured four hours following administration of the drug.&nbsp; The following distribution of plasma drug concentration in these subjects is obtained.</P><BLOCKQUOTE dir=ltr><P><img id=\"9179\"  src=\"https://www.uworld.com/media/ActylationQ1.gif\" draggable=\"false\" ></BLOCKQUOTE><P>Variation of which of the following processes provides the best explanation for the shaded area of the curve?</P>",
      "choices": [
        {
          "id": 1,
          "text": "Methylation"
        },
        {
          "id": 2,
          "text": "Glucuronidation"
        },
        {
          "id": 3,
          "text": "Hydrolysis"
        },
        {
          "id": 4,
          "text": "Acetylation"
        },
        {
          "id": 5,
          "text": "Amine oxidation"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Pharmacogenomics</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><P>The rate and extent of drug metabolism normally varies from person to person.&nbsp; These slight interpersonal variations in the ability to metabolize drugs are typically reflected graphically by a unimodal distribution, usually in the shape of a bell curve, when plasma levels of drug are measured at a fixed time following a fixed dose of drug.&nbsp; This is the method that was used to generate the graph given in the question stem.&nbsp; With most drugs, the majority of people fall within one standard deviation and 95% of people fall within two standard deviations of the population mean of plasma concentration.&nbsp; A single peak in this type of graph indicates that the population being tested possesses a similar genetic drug metabolizing capacity.</P><P>A bimodal (discontinuous, polymorphic) curve, as shown in the question stem, results from the presence of two apparently distinct groups within the study population and suggests a pharmacogenetic polymorphism in drug metabolizing capacity.&nbsp; In other words, the two peaks indicate two sets of responders to the drug within the population: one that rapidly converts the drug into its metabolite (considered normals) and another that converts the drug slowly, leading to accumulation of the original drug in the plasma.</P><P>Isoniazid is metabolized by acetylation to N-acetyl-isoniazid in the hepatic microsomal system by the enzyme N-acetyl transferase and is subsequently excreted in the urine.&nbsp; The first and second peaks in the above graph represent fast and slow acetylators, respectively.&nbsp; Slow acetylators of isoniazid also metabolize (acetylate) dapsone, hydralazine, and procainamide slowly, causing accumulation of these drugs as well.&nbsp; Slow acetylators of these drugs are at increased risk of toxic effects, while fast acetylators may require much higher therapeutic doses to achieve a therapeutic effect.</P><P><B>(Choice A)</B> Methylation is an important drug biotransformation method to consider when prescribing drugs such as azathioprine and 6-mercaptopurine, drugs used in the treatment of some inflammatory disorders of the bowel and skin.</P><P><B>(Choice B)</B> Glucuronidation is a biotransformation pathway utilized for the metabolism of numerous drugs as well as endogenous substances such as bilirubin.&nbsp; No bimodality has been described with this pathway, but conditions such as Gilbert syndrome involve dysfunction of the glucuronyl transferase system that can lead to toxic accumulation of some drugs.</P><P><B>(Choice C)</B> Hydrolysis occurs with enzymes such as esterases and amidases.&nbsp; Isoniazid is not metabolized by this pathway, and hydrolysis does not exhibit polymorphic metabolism.</P><P><B>(Choice E)</B> Amine oxidation is usually undertaken by monoamine oxidases or by cytochrome oxidative deamination.&nbsp; Neither process metabolizes isoniazid nor exhibits bimodality.</P><P><B>Educational Objective:<BR></B>Isoniazid is metabolized by acetylation.&nbsp; The speed with which a patient is able to acetylate drugs depends on whether they are genetically \"fast\" or \"slow\" acetylators.&nbsp; The presence of fast and slow acetylators within the same population results in a bimodal distribution of the speed of isoniazid metabolism.&nbsp; Slow acetylators are at increased risk of adverse side effects.</P>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1712",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 48-year-old woman with metastatic cervical cancer is brought to the emergency department due to worsening lethargy for the past several days.&nbsp; A year ago, the patient was diagnosed with cervical cancer, which has progressed despite chemotherapy treatment and metastasized to the liver and lungs.&nbsp; She has also developed bilateral hydronephrosis and renal failure due to ureteral compression by the tumor.&nbsp; The patient is receiving palliative care, and her pain has been adequately controlled with a stable dose of oral morphine.&nbsp; Temperature is 36.7 C (98 F), blood pressure is 110/62 mm Hg, pulse is 92/min, and respirations are 10/min.&nbsp; On physical examination, the patient is somnolent and responds to painful stimuli only.&nbsp; The pupils are small and sluggish to react.&nbsp; The lungs are clear to auscultation, and heart sounds are normal.&nbsp; The abdomen is soft and nondistended.&nbsp; Arterial blood gas analysis shows respiratory acidosis.&nbsp; Which of the following medication-related events most likely precipitated her current condition?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Decreased first-pass metabolism"
        },
        {
          "id": 2,
          "text": "Decreased hepatic metabolism"
        },
        {
          "id": 3,
          "text": "Increased enterohepatic circulation"
        },
        {
          "id": 4,
          "text": "Increased metabolite accumulation"
        },
        {
          "id": 5,
          "text": "Increased volume of distribution"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Opioids</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Morphine</strong> stimulates mu opioid receptors to provide the desired effect of analgesia, but in doing so can also precipitate many undesired effects.&nbsp; This patient has multiple signs of <strong>opioid toxicity</strong>, including miosis (ie, pinpoint pupils), <strong>respiratory depression</strong> (evidenced by slow respiratory rate and respiratory acidosis), and CNS depression (eg, <strong>somnolence</strong>, coma).&nbsp; Morphine is primarily metabolized by the liver via glucuronidation to form <strong>2 major metabolites</strong>.&nbsp; These metabolites, morphine-3-glucoronide and <strong>morphine-6-glucoronide</strong>, then undergo <strong>renal elimination</strong> via excretion in the urine.&nbsp; Because the metabolites are metabolically active, <strong>renal dysfunction</strong> can lead to <strong>metabolite accumulation</strong> and opioid toxicity.&nbsp; Morphine-6-glucoronide is particularly responsible for toxicity, acting as a more potent mu opioid receptor agonist than morphine itself.</p><p>Due to its metabolically active and renally cleared metabolites, morphine requires careful monitoring when used in patients with renal dysfunction.&nbsp; When opioid pain control is needed in such patients, fentanyl or hydromorphone is often preferred as these drugs are predominantly hepatically cleared.</p><p><strong>(Choice A)</strong>&nbsp; Decreased first-pass metabolism occurs with drugs that are given by a route other than orally, allowing the drug to reach the systemic circulation without passing through the portal circulation and the liver.&nbsp; Examples include drugs that are administered sublingually, rectally, or intravenously.</p><p><strong>(Choice B)</strong>&nbsp; Decreased hepatic metabolism is common in the elderly or in patients with advanced liver disease (eg, cirrhosis).&nbsp; Although this patient has metastatic disease to the liver, accumulation of morphine metabolites is a more likely cause of toxicity in the setting of known renal failure.</p><p><strong>(Choice C)</strong>&nbsp; Enterohepatic circulation occurs when a drug undergoes biliary excretion into the small intestine, where it is then reabsorbed back into the bloodstream.&nbsp; Such drugs typically demonstrate a prolonged half-life.&nbsp; Although the phenomenon may account for a prolonged duration of therapeutic effect, it rarely accounts for toxicity.</p><p><strong>(Choice E)</strong>&nbsp; Drugs with a high volume of distribution (eg, amiodarone) are well distributed in the tissues and have a long half-life.&nbsp; These drugs may demonstrate prolonged therapeutic and/or adverse effects after discontinuation.</p><p><strong>Educational objective:</strong><br>Morphine generates 2 major metabolites that are metabolically active and renally cleared.&nbsp; These metabolites can accumulate in the bloodstream of patients with renal dysfunction and lead to opioid toxicity, evidenced by miosis, respiratory depression, and CNS depression.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17112",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 78-year-old man was found to have a perihilar mass on screening CT scan.&nbsp; The patient&#39;s medical history is remarkable for chronic obstructive pulmonary disease, for which he takes albuterol inhalers as needed.&nbsp; He has smoked a pack of cigarettes daily for the last 50 years and does not drink alcohol or use illicit drugs.&nbsp; The patient is admitted for bronchoscopy and is premedicated with intramuscular atropine and becomes acutely restless, disoriented, and combative.&nbsp; Temperature is 38.1 C (100.5 F), blood pressure is 116/72 mm Hg, pulse is 110/min, and respirations are 15/min.&nbsp; Oxygen saturation is 99% on room air.&nbsp; On physical examination, his pupils are widely dilated and nonreactive to light.&nbsp; ECG shows sinus tachycardia.&nbsp; Which of the following agents will reverse all of this patient&#39;s signs and symptoms?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Diazepam"
        },
        {
          "id": 2,
          "text": "Edrophonium"
        },
        {
          "id": 3,
          "text": "Haloperidol"
        },
        {
          "id": 4,
          "text": "Neostigmine"
        },
        {
          "id": 5,
          "text": "Physostigmine"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Anticholinergics</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t38428\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Anticholinergic toxicity</strong></p></td></tr><tr><td><p align=\"center\"><strong>Symptom</strong></p></td><td><p align=\"center\"><strong>Mechanism</strong></p></td></tr><tr><td><p align=\"center\"><strong>&quot;Hot as a hare&quot;</strong><br />&uarr; Body temperature</p></td><td><ul><li>&darr; Sweating leads to &darr; heat dissipation</li></ul></td></tr><tr><td><p><strong>&quot;Dry as a bone&quot;</strong><br />&darr; Secretions (eg,&nbsp;mucous membranes, sweat glands)</p></td><td><ul><li>&darr; Glandular secretion &amp; smooth muscle contraction</li></ul></td></tr><tr><td><p align=\"center\"><strong>&quot;Red as a beet&quot;</strong><br />Flushed skin</p></td><td><ul><li>Superficial vasodilation from &uarr;&nbsp;body heat</li></ul></td></tr><tr><td><p align=\"center\"><strong>&quot;Blind as a bat&quot;</strong><br />Cycloplegia, mydriasis</p></td><td><ul><li>Paralysis of ciliary muscle &amp; iris sphincter</li></ul></td></tr><tr><td><p align=\"center\"><strong>&quot;Mad as a hatter&quot;</strong><br />Altered mental status</p></td><td><ul><li>Permeates blood-brain barrier &amp; affects CNS pathways</li></ul></td></tr><tr><td><p align=\"center\"><strong>&quot;Full as a flask&quot;</strong><br />Constipation,<br />urinary retention</p></td><td><ul><li>&darr; Intestinal smooth muscle contraction</li><li>&darr; Detrusor contraction &amp; &darr;&nbsp;internal urethral sphincter relaxation</li></ul></td></tr><tr><td><p align=\"center\"><strong>&quot;Fast as a fiddle&quot;</strong></p><p align=\"center\">Tachycardia</p></td><td><ul><li>&darr; Vagal tone at the sinoatrial node</li></ul></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p><strong>Atropine</strong> is an anticholinergic medication that can be administered prior to bronchoscopy to decrease respiratory mucus secretions and promote bronchodilation.&nbsp; <strong>Anticholinergic</strong> drugs competitively inhibit the muscarinic acetylcholine receptor both centrally (leading to delirium, coma, and respiratory failure) and peripherally (see toxidrome in table).&nbsp; The elderly are at particularly high risk of developing anticholinergic toxicity, likely due to decreased renal and hepatic clearance.</p><p><strong>Cholinesterase inhibitors</strong> overcome this toxicity by inhibiting the degradation of acetylcholine, thereby increasing the concentration of acetylcholine at the synaptic cleft.&nbsp; Central nervous system (CNS) penetration and reversal of central symptoms are dependent on chemical structure:</p><ul><li><p><strong>Tertiary amines</strong> (eg, <strong>physostigmine</strong>, galantamine, donepezil, rivastigmine) are lipophilic (nonpolar) and can easily cross the blood-brain barrier to reverse both central and peripheral symptoms.</p></li><li><p>Quaternary amines (eg, neostigmine, edrophonium, pyridostigmine) are hydrophilic (polarized) and do not readily cross the blood-brain barrier.&nbsp; These drugs reverse peripheral symptoms only <strong>(Choices B and D)</strong>.</p></li></ul><p><strong>(Choices A and C)</strong>&nbsp; Both diazepam and haloperidol can be used for sedation or cases of severe agitation.&nbsp; Haloperidol is an antipsychotic that blocks dopamine receptors in the CNS, and diazepam is a long-acting benzodiazepine that positively modulates GABA-A activity.&nbsp; Neither medication reverses the peripheral anticholinergic manifestations (eg, mydriasis, tachycardia).</p><p><strong>Educational objective:</strong><br>Physostigmine is a cholinesterase inhibitor with a tertiary ammonium structure that can reverse both the central and peripheral nervous system symptoms of anticholinergic toxicity.&nbsp; Neostigmine, edrophonium, and pyridostigmine have a quaternary ammonium structure that limits central nervous system penetration.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1564",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 71-year-old man with chronic stable angina comes to the office for routine follow-up.&nbsp; He has occasional episodes of chest pain that improve after taking sublingual nitroglycerin.&nbsp; The patient also has a history of hypertension and hypercholesterolemia and takes multiple medications for his conditions.&nbsp; Blood pressure is 140/80 mm Hg and pulse is 68/min and regular.&nbsp; Examination reveals normal heart sounds.&nbsp; While discussing a plan to start isosorbide dinitrate therapy, the patient becomes concerned about the high dose of oral isosorbide dinitrate compared to sublingual nitroglycerin.&nbsp; Which of the following is the most likely reason for using a high dose of oral nitrate?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Drug tolerance prevention"
        },
        {
          "id": 2,
          "text": "High first-pass metabolism"
        },
        {
          "id": 3,
          "text": "High serum protein binding"
        },
        {
          "id": 4,
          "text": "High volume of distribution"
        },
        {
          "id": 5,
          "text": "Low intestinal absorption"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Nitrates</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Nitrates, beta blockers, and calcium channel blockers are the mainstay of therapy for patients with chronic stable angina.&nbsp; Sublingual nitroglycerin is the therapy of choice in acute episodes for immediate relief of angina and for prevention of angina prior to engaging in strenuous physical activity.&nbsp; Chronic nitrate therapy with long-acting oral formulations (isosorbide dinitrate or mononitrate) is used to prevent recurrent anginal episodes in patients with chronic stable angina.</p><p>Sublingual nitroglycerin is absorbed rapidly from oral mucosa directly into the venous circulation and has a rapid onset of action within 2-5 minutes.&nbsp; Long-acting <strong>isosorbide dinitrate</strong> is absorbed via the gastrointestinal tract and undergoes <strong>extensive first-pass metabolism</strong> in the liver prior to release in the systemic circulation.&nbsp; This leads to <strong>low bioavailability</strong> and the need for much higher doses of oral formulations as compared to sublingual nitroglycerin.</p><p><strong>(Choice A)</strong>&nbsp; Chronic nitrate therapy on a regular basis leads to nitrate tolerance, with attenuation of blood pressure response and anti-anginal effects.&nbsp; Higher doses do not prevent nitrate tolerance.&nbsp; On the contrary, use of sublingual nitroglycerin on an intermittent, as-needed basis (nitrate-free intervals) prevents the development of nitrate tolerance.</p><p><strong>(Choices C and D)</strong>&nbsp; The oral nitrate preparations do not have high serum protein binding or volume of distribution.</p><p><strong>(Choice E)</strong>&nbsp; Isosorbide dinitrate has rapid and nearly complete intestinal absorption.&nbsp; Its low bioavailability is due to considerable first-pass hepatic metabolism.</p><p><strong>Educational objective: </strong><br>Isosorbide dinitrate has a low bioavailability due to extensive first-pass hepatic metabolism prior to release in systemic circulation.&nbsp; Sublingual nitroglycerin is absorbed directly from oral mucosa into the venous circulation and has a higher bioavailability.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "139",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 56-year-old woman comes to the emergency department due to 3 days of frequent urination, suprapubic pain, dysuria, and progressive hematuria.&nbsp; She has had no fevers or chills.&nbsp; The patient has a history of lymph-node-positive breast cancer that was diagnosed following a routine mammogram.&nbsp; A month ago, she began treatment with systemic chemotherapy.&nbsp; Temperature is 37.1 C (98.8 F).&nbsp; Suprapubic tenderness is present on abdominal examination.&nbsp; Hemoglobin is 9.8 g/dL.&nbsp; Urinalysis shows numerous red blood cells but no leukocyte esterase or bacteria.&nbsp; Which of the following could have prevented this patient&#39;s current condition?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Dexrazoxane"
        },
        {
          "id": 2,
          "text": "Filgrastim"
        },
        {
          "id": 3,
          "text": "Folinic acid"
        },
        {
          "id": 4,
          "text": "Mesna"
        },
        {
          "id": 5,
          "text": "Ondansetron"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Chemotherapy</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This patient who recently received systemic chemotherapy for breast cancer and now has progressive hematuria and suprapubic tenderness most likely has <strong>hemorrhagic cystitis</strong> caused by a nitrogen mustard-based chemotherapeutic agent, such as <strong>cyclophosphamide</strong> or one of its analogs (eg, ifosfamide).&nbsp; These agents are metabolized by the kidneys into <strong>acrolein</strong>, which is then excreted in the urine.&nbsp; Acrolein is toxic to uroepithelial cells and can cause cell death and necrosis if allowed to be in contact with these cells for a prolonged period.</p><p>Hemorrhagic cystitis associated with nitrogen mustard-based chemotherapy can be <strong>prevented</strong> by aggressive hydration and the coadministration of <strong>mesna</strong> (2-mercaptoethanesulfonate), a sulfhydryl compound that binds and inactivates the toxic metabolites of the chemotherapeutic agents in the urine.</p><p><strong>(Choice A)</strong>&nbsp; Dexrazoxane is an iron-chelating agent that can help prevent anthracycline-induced (eg, doxorubicin) cardiotoxicity.</p><p><strong>(Choice B)</strong>&nbsp; Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes in patients with neutropenia, as can occur after chemotherapy.&nbsp; This patient is afebrile, and her urinalysis is not suggestive of a urinary tract infection.</p><p><strong>(Choice C)</strong>&nbsp; Leucovorin, or folinic acid, is a drug used in the treatment of methotrexate overdose.&nbsp; It also enhances the cytotoxic action of 5-fluorouracil (5-FU) and is used in combination with 5-FU in some cases of colorectal cancer.</p><p><strong>(Choice E)</strong>&nbsp; Ondansetron inhibits serotonin 5-HT<font size=\"2\"><sub>3</sub></font> receptors and is used primarily to treat nausea and vomiting following chemotherapy.</p><p><strong>Educational objective:</strong><br>Hemorrhagic cystitis during therapy with cyclophosphamide or ifosfamide is caused by the urinary excretion of the toxic metabolite acrolein.&nbsp; It can be prevented by aggressive hydration, bladder irrigation, and administration of mesna, a sulfhydryl compound that binds acrolein in the urine.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1816",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 38-year-old woman comes to the office to discuss motion sickness.&nbsp; She is currently feeling well.&nbsp; The patient is planning a vacation cruise and has previously experienced severe nausea and vomiting while sailing.&nbsp; She has 4 children, and her past medical history is notable only for a tubal ligation.&nbsp; The patient does not smoke and drinks only moderate quantities of alcohol.&nbsp; She is not currently taking any medications.&nbsp; Physical examination, including otologic and neurologic examinations, is normal.&nbsp; After the appropriate drug therapy is recommended, this patient should be counseled regarding which of the following side effects?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Cough"
        },
        {
          "id": 2,
          "text": "Diarrhea"
        },
        {
          "id": 3,
          "text": "Dry mouth"
        },
        {
          "id": 4,
          "text": "Frequent urination"
        },
        {
          "id": 5,
          "text": "Nasal congestion"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Motion sickness</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><div id=\"div_t81699\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"3\"><p align=\"center\"><strong>Characteristics of antiemetic drugs</strong></p></td></tr><tr><td><p align=\"center\"><strong>Drug class</strong></p></td><td><p align=\"center\"><strong>Examples</strong></p></td><td><p align=\"center\"><strong>Clinical uses</strong></p></td></tr><tr><td><p align=\"center\"><strong>Antimuscarinics (anticholinergics)</strong></p></td><td><ul><li>Scopolamine</li></ul></td><td rowspan=\"2\"><ul><li>Motion sickness</li><li>Hyperemesis gravidarum (promethazine)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Antihistamines</strong></p></td><td><ul><li>Diphenhydramine</li><li>Meclizine</li><li>Promethazine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Dopamine receptor antagonists</strong></p></td><td><ul><li>Prochlorperazine</li><li>Metoclopramide</li></ul></td><td rowspan=\"3\"><ul><li>Chemotherapy-induced emesis</li></ul></td></tr><tr><td><p align=\"center\"><strong>Serotonin (5-HT<sub>3</sub>) receptor antagonists</strong></p></td><td><ul><li>Ondansetron</li><li>Granisetron</li></ul></td></tr><tr><td><p align=\"center\"><strong>Neurokinin 1 (NK1) receptor antagonists</strong></p></td><td><ul><li>Aprepitant</li><li>Fosaprepitant</li></ul></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div></p><p>Perception of motion and orientation is determined by input from the vestibular, visual, and somatosensory systems.&nbsp; These 3 systems are usually congruent, but conflicting input can lead to <strong>motion sickness</strong>, characterized by nausea, dizziness, and autonomic symptoms (eg, diaphoresis).&nbsp; Integration of these sensory pathways occurs in the <strong>vestibular nuclei</strong> via muscarinic and histaminic neurotransmission.&nbsp; As such, <strong>antimuscarinic</strong> agents (eg, scopolamine) and first-generation <strong>antihistamines</strong> (eg, meclizine, dimenhydrinate) are most effective for management of motion sickness.&nbsp; <strong>Anticholinergic side effects</strong> are common with these medications and may include blurry vision, dry mouth, urinary retention, and constipation.</p><p><strong>(Choices A, D, and E)</strong>&nbsp; Cough, frequent urination, and nasal congestion are characteristic of stimulation rather than blockade of muscarinic pathways.</p><p><strong>(Choice B)</strong>&nbsp; Diarrhea may be seen with dopamine receptor antagonists (eg, metoclopramide), but these drugs are primarily used for visceral (eg, diabetic gastroparesis), rather than vestibular, nausea.</p><p><strong>Educational objective:</strong><br>Antimuscarinic agents and antihistamines with antimuscarinic action are most effective for motion sickness prevention.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "175",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 65-year-old man is brought to the emergency department after developing sudden-onset right-side weakness and difficulty speaking.&nbsp; He has a history of paroxysmal atrial fibrillation and has been taking warfarin for the past several years with a stable prothrombin time.&nbsp; His wife adds that he started taking a new drug 2 weeks ago, but she does not remember its name.&nbsp; Physical examination shows right hemiplegia, right hemisensory loss, expressive aphasia, and right homonymous hemianopia.&nbsp; MRI of the head shows a left middle cerebral artery territory infarct.&nbsp; Transesophageal echocardiogram reveals a small thrombus in the left atrium.&nbsp; This patient most likely started taking which of the following drugs recently?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Amiodarone"
        },
        {
          "id": 2,
          "text": "Cimetidine"
        },
        {
          "id": 3,
          "text": "Ciprofloxacin"
        },
        {
          "id": 4,
          "text": "Clarithromycin"
        },
        {
          "id": 5,
          "text": "Fluconazole"
        },
        {
          "id": 6,
          "text": "Penicillin V"
        },
        {
          "id": 7,
          "text": "St John&#39;s wort"
        }
      ],
      "correct_choice_id": 7,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><div id=\"div_t82165\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Cytochrome P450 (CYP450) interactions</strong></p></td></tr><tr><td><p align=\"center\"><strong>Inducers</strong></p></td><td><p align=\"center\"><strong>Inhibitors</strong></p></td></tr><tr><td><p>Carbamazepine</p><p>Barbiturates</p><p>Phenytoin</p><p>Rifampin</p><p>Griseofulvin</p><p>St. John&rsquo;s wort</p><p>Modafinil</p><p>Cyclophosphamide</p></td><td><p>Amiodarone</p><p>Cimetidine</p><p>Fluoroquinolones</p><p>Clarithromycin</p><p>Azole antifungals</p><p>Grapefruit juice</p><p>Isoniazid</p><p>Ritonavir (protease inhibitors)</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div></p><p>This patient has suffered a <strong>thromboembolic stroke</strong>, likely the result of a dislodged left atrial thrombus that formed due to an adverse drug interaction leading to <strong>inadequate anticoagulation</strong>.&nbsp; Many substances cause induction or inhibition of cytochrome P450 (CYP450) hepatic microsomal enzymes, which are responsible for the majority of drug metabolism.&nbsp; CYP450 interactions should be considered when selecting and dosing medications, as changes in enzyme activity affect the rate of drug metabolism.</p><p>Alterations in plasma drug levels are especially important when considering medications that are vital to a patient&#39;s health or have a high propensity for toxicity, such as warfarin.&nbsp; For example, <strong>warfarin</strong> can interact with <strong>St John&#39;s wort</strong>, an over-the-counter medicinal herb known for both its anti-inflammatory and antidepressant properties.&nbsp; St John&#39;s wort <strong>induces hepatic CYP450 enzymes</strong>, resulting in increased warfarin metabolism, decreased drug levels, and inadequate anticoagulation.</p><p><strong>(Choices A, B, C, D, and E)</strong>&nbsp; These drugs are known to inhibit CYP450 enzymes and increase warfarin levels, leading to an increased risk of bleeding complications.</p><p><strong>(Choice F)</strong>&nbsp; Oral penicillin V and warfarin do not have any significant interactions.&nbsp; Antibiotics in general reduce the intestinal bacterial load, which reduces vitamin K synthesis and could potentiate warfarin&#39;s anticoagulant effects.</p><p><strong>Educational objective:</strong><br>St John&#39;s wort induces cytochrome P450 hepatic microsomal enzymes.&nbsp; As a result, a wide variety of drugs that are metabolized by these enzymes, such as warfarin, will have lower plasma concentrations and decreased efficacy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1777",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 52-year-old woman comes to the emergency department due to recurrent right lower extremity swelling, pain, and erythema.&nbsp; The patient&#39;s medical history includes type 2 diabetes mellitus and depression.&nbsp; Her medications include metformin, paroxetine, and a multivitamin.&nbsp; The patient is diagnosed with cellulitis, admitted to the hospital, and started on antibiotics.&nbsp; She is continued on her home medications.&nbsp; Three days later, the patient becomes agitated and delirious with severe abdominal cramps and diarrhea.&nbsp; Temperature is 39.2 C (102.6 F), blood pressure is 180/100 mm Hg, and pulse&nbsp;is 120/min.&nbsp; On examination, the patient is diaphoretic and tremulous, and her pupils are dilated.&nbsp; Bilateral hyperreflexia and ankle clonus are present.&nbsp; She begins to have seizures.&nbsp; Which of the following antibiotics was the patient most likely given to treat the cellulitis?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Clindamycin"
        },
        {
          "id": 2,
          "text": "Doxycycline"
        },
        {
          "id": 3,
          "text": "Linezolid"
        },
        {
          "id": 4,
          "text": "Penicillin"
        },
        {
          "id": 5,
          "text": "Vancomycin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Serotonin toxicity</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t43596\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Serotonin t</strong><strong>oxicity</strong></p></td></tr><tr><td><p align=\"center\"><strong>Causes</strong></p></td><td><ul><li>Serotonergic medications, especially in combination (eg, SSRI/SNRI, TCA, tramadol)</li><li>Drug interactions: Serotonergic medication &amp; MAOI or linezolid</li><li>Intentional overdose of serotonergic medications</li><li>Serotonergic drugs of abuse (eg, MDMA)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Mental status changes (eg, anxiety, agitation, delirium)</li><li>Autonomic dysregulation (eg, diaphoresis, hypertension, tachycardia, hyperthermia, vomiting, diarrhea)</li><li>Neuromuscular hyperactivity (eg, tremor, myoclonus, hyperreflexia)</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>MAOI</strong> = monoamine oxidase inhibitor; <strong>SNRI</strong> = serotonin-norepinephrine reuptake inhibitor; <strong>SSRI </strong>= selective serotonin reuptake inhibitor; <strong>TCA</strong> = tricyclic antidepressant.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p><strong>Serotonin toxicity</strong> is characterized by a triad of <strong>autonomic instability</strong> (eg, hyperthermia, hypertension, tachycardia), <strong>altered mental status</strong> (eg, agitation, confusion), and <strong>neuromuscular hyperactivity</strong> (eg, tremor, hyperreflexia, myoclonus), as well as gastrointestinal symptoms and diaphoresis.&nbsp; It is due to an increased serotonergic effect in the central nervous system (eg, increased 5-HT1A and 5-HT2A receptor stimulation).</p><p>Serotonin toxicity rarely occurs with a single serotonergic drug used at therapeutic doses.&nbsp; More commonly, it is due to the combined effects of several serotonergic medications, overdose, and/or a drug-drug interaction.&nbsp; Serotonin effect is increased when a <strong>monoamine oxidase inhibitor</strong> (MAOI) is <strong>combined</strong> with a <strong>serotonergic antidepressant</strong> (selective serotonin reuptake inhibitor [SSRI], serotonin-norepinephrine reuptake inhibitor, or tricyclic antidepressant).</p><p>Linezolid is used to treat infections caused by gram-positive bacteria, particularly vancomycin-resistant enterococcus and methicillin-resistant <em>Staphylococcus aureus</em>.&nbsp; <strong>Linezolid has MAOI activity</strong> and therefore can precipitate serotonin toxicity with concomitant use of an SSRI (eg, paroxetine) or with other serotonergic medications.</p><p><strong>(Choices A, B, D, and E)</strong>&nbsp; Clindamycin, doxycycline, penicillin, and vancomycin do not have MAOI effects.&nbsp; They do not cause serotonin toxicity when combined with a serotonergic antidepressant.</p><p><strong>Educational objective:</strong><br>Serotonin toxicity is characterized by a triad of autonomic instability, altered mental status, and neuromuscular irritability.&nbsp; It may develop when a monoamine oxidase inhibitor (MAOI) antidepressant or a non-antidepressant with MAOI activity (eg, linezolid) is combined with a serotonergic medication such as a selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, or tricyclic antidepressant.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "8323",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 68-year-old man comes to the office with a 6-week history of muscle pain and fatigue.&nbsp; He has achy pain that is not related to activity.&nbsp; The patient has tried warm compresses and over-the-counter analgesics without relief.&nbsp; Past medical history is significant for hypertension, mixed hyperlipidemia, and coronary artery disease with an acute myocardial infarction 2 years ago.&nbsp; Physical examination shows diffuse tenderness in the proximal muscles of the upper and lower extremities.&nbsp; Serum creatine kinase activity is elevated.&nbsp; Which of the following drug combinations is most likely responsible for this patient&#39;s condition?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Atorvastatin and cholestyramine"
        },
        {
          "id": 2,
          "text": "Atorvastatin and ezetimibe"
        },
        {
          "id": 3,
          "text": "Atorvastatin and gemfibrozil"
        },
        {
          "id": 4,
          "text": "Gemfibrozil and ezetimibe"
        },
        {
          "id": 5,
          "text": "Niacin and ezetimibe"
        },
        {
          "id": 6,
          "text": "Niacin and gemfibrozil"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Drug induced myopathy</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Statins (eg, atorvastatin) are the first-line therapy for most patients with hypercholesterolemia and are useful in primary and secondary prevention of acute coronary events.&nbsp; Statins inhibit HMG-CoA reductase, the enzyme responsible for the rate-limiting step in synthesis of <a href=\"2896\">cholesterol</a>.&nbsp; Statins lower total cholesterol, LDL, and triglyceride levels.</p><p>The primary side effects of statins include myopathy and hepatitis.&nbsp; <strong>Statin-associated myopathy</strong> is usually characterized by mild muscular pain and resolves with discontinuation of the medication.&nbsp; However, some patients will develop severe myopathy with striking elevations in creatine kinase levels and occasional rhabdomyolysis.&nbsp; The risk of severe myopathy is increased when statins are given concurrently with fibrates (particularly <strong>gemfibrozil</strong>), which impair the hepatic clearance of statins and lead to excessive blood levels.&nbsp; An increased risk of statin myopathy is also likely with concurrent use of niacin or ezetimibe, but to a lesser extent <strong>(Choice B)</strong>.</p><p><strong>(Choice A)</strong>&nbsp; Concurrent use of bile acid sequestrants (eg, cholestyramine) with statins does not increase the risk of myopathy.&nbsp; However, bile acid sequestrants can reduce the gastrointestinal absorption of statins.</p><p><strong>(Choice D)</strong>&nbsp; Fibrates can increase drug levels of ezetimibe but this does not have a significant impact on its side effects, which are generally mild and not dose-related.&nbsp; Ezetimibe does not alter the pharmacokinetics of fibrates and does not substantially influence their adverse effects.</p><p><strong>(Choices E and F)</strong>&nbsp; The primary adverse effects of niacin include flushing, hyperglycemia, and hepatotoxicity.&nbsp; There are no significant interactions with the concurrent use of niacin and ezetimibe or gemfibrozil.</p><p><strong>Educational objective:</strong><br>The primary side effects of statins include myopathy and hepatitis.&nbsp; Fibrates such as gemfibrozil can impair hepatic clearance of statins, increasing the risk of severe myopathy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "778",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A clinical trial is being conducted to evaluate the safety and efficacy of a novel therapy to treat refractory Crohn disease.&nbsp; The medication is a monoclonal antibody against the &#945;4&#946;7 integrin, which inhibits migration of T-lymphocytes into the intestinal parenchyma and produces a gut-selective anti-inflammatory effect.&nbsp; Patients who have active, moderate to severe Crohn disease and have failed conventional therapy are enrolled in the study.&nbsp; Many of these patients have renal or hepatic dysfunction, and some take other medications that affect cytochrome P450 enzymes.&nbsp; Which of the following is the most appropriate dose adjustment in this patient population to decrease drug toxicity?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Higher dose in patients taking cytochrome P450 inducers"
        },
        {
          "id": 2,
          "text": "Lower dose in patients with decreased glomerular filtration"
        },
        {
          "id": 3,
          "text": "Lower dose in patients with hepatocellular dysfunction"
        },
        {
          "id": 4,
          "text": "Lower dose in patients with renal tubular dysfunction"
        },
        {
          "id": 5,
          "text": "No dose adjustment necessary"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Biologic agents</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Monoclonal antibodies</strong> (mAbs) are used to treat a growing variety of malignant (eg, leukemia/lymphoma, melanoma) and autoimmune diseases (eg, Crohn disease, rheumatoid arthritis).&nbsp; The therapeutic effect of mAbs is achieved by binding to their target antigen in the plasma or on the cell surface and <strong>blocking deleterious receptor interactions</strong> or triggering a <strong>cytotoxic immune response</strong> against abnormal cells.</p><p>Because of their large molecular size, mAbs cannot be administered orally and must be given via intravenous or subcutaneous/intramuscular routes.&nbsp; Unlike most other drugs, mAbs are <strong>not eliminated by hepatic or renal clearance</strong>, but are instead removed from the body in 2 primary ways:</p><ul><li><p>Target-mediated drug clearance: mAbs directed against cell surface antigens undergo internalization (receptor-mediated endocytosis) upon binding to their targets, removing them from the circulation</p></li><li><p>Nonspecific clearance: Immunoglobulins are constitutively taken up by reticuloendothelial macrophages (via binding to Fc receptors) and vascular endothelial cells (via pinocytosis)</p></li></ul><p>Once internalized, immunoglobulins are <strong>catabolized into amino acids</strong> within lysosomes.</p><p><strong>(Choices A and C)</strong>&nbsp; Many drugs undergo modifications by the cytochrome P450 system and subsequent conjugation reactions within hepatocytes that help facilitate excretion of the drug into the urine or bile.&nbsp; In contrast, immunoglobulins are not metabolized by these systems, but rather broken down by proteolytic enzymes.</p><p><strong>(Choices B and D)</strong>&nbsp; Immunoglobulins are too large to undergo substantial filtration at the glomerular basement membrane and are not secreted by the renal tubules.&nbsp; Therefore, renal dysfunction does not significantly affect monoclonal antibody clearance.</p><p><strong>Educational objective:</strong><br>Monoclonal antibodies (mAbs) are not eliminated by hepatic or renal clearance. Therefore, no dose adjustment is necessary with impaired hepatic/renal function or use of cytochrome P450 inducers or inhibitors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "14531",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A researcher is conducting a retrospective study on breast cancer recurrence.&nbsp; Records of a number of patients with hormone receptor-positive, early-stage breast cancer who received adjuvant therapy with tamoxifen were evaluated.&nbsp; Various clinical, demographic, and drug concentration data were analyzed.&nbsp; A comparison of patients who had disease recurrence with those who remained cancer free showed that some of the relapsed patients had lower serum concentrations of endoxifen and 4-hydroxytamoxifen, the active metabolites of tamoxifen.&nbsp; Which of the following is the most likely cause of the drug&#39;s ineffectiveness in this subset of patients?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Activating mutation affecting a downstream signal transducer"
        },
        {
          "id": 2,
          "text": "Decreased hepatic N-acetyltransferase activity"
        },
        {
          "id": 3,
          "text": "Deficiency of thiopurine methyltransferase enzyme"
        },
        {
          "id": 4,
          "text": "Overexpression of P-glycoprotein in the tumor cells"
        },
        {
          "id": 5,
          "text": "Polymorphism of a cytochrome P450 enzyme"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Pharmacogenomics</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Cytochrome P450 (CYP) enzymes</strong> are a group of heme-containing proteins that are responsible for the majority of <strong>drug metabolism</strong>, which occurs predominately in the liver.&nbsp; Various CYP subtypes exist, with CYP3A, CYP2D, and CYP2C as the most active subtypes involved in drug metabolism.&nbsp; These enzymes generally function to deactivate drugs and facilitate excretion from the body by improving water solubility.&nbsp; However, they also metabolize certain compounds to their active forms.</p><p><strong>Polymorphisms</strong> may occur in the genes coding for these enzymes, altering their expression or activity.&nbsp; Three important phenotypes exist:&nbsp; <strong>poor, intermediate, and rapid metabolizer</strong>.&nbsp; Identifying these variations on an individual basis provides a framework for optimizing therapy, predicting treatment efficacy, and minimizing toxicity.</p><p><strong>Tamoxifen</strong>, a selective estrogen receptor modulator used in the treatment of estrogen receptor-positive breast cancer, is a prodrug metabolized by CYP2D to its <strong>active metabolite, endoxifen</strong>.&nbsp; Patients with genetic polymorphisms resulting in poor CYP2D activity are exposed to decreased levels of the active metabolite and have a higher risk of disease relapse.</p><p><strong>(Choice A)</strong>&nbsp; Activation of downstream signal transducer proteins, such as KRAS, leads to activation of transcription factors that promote cell growth.&nbsp; Mutations in the <em>KRAS</em> gene are associated with the development of colorectal and lung cancers.</p><p><strong>(Choice B)</strong>&nbsp; Decreased activity of hepatic N-acetyltransferase results in a diminished ability to metabolize drugs such as isoniazid and sulfonamides, leading to an increased likelihood of toxicity.</p><p><strong>(Choice C)</strong>&nbsp; Thiopurine methyltransferase is responsible for the metabolism of thiopurine compounds such as the immunosuppressive drug 6-mercaptopurine.&nbsp; Enzyme deficiency leads to increased drug toxicity.</p><p><strong>(Choice D)</strong>&nbsp; P-glycoprotein is a cell membrane protein that drives efflux of a number of substances out of the cell.&nbsp; Overexpression of p-glycoprotein in tumor cells has been identified as a cause of multidrug resistance.</p><p><strong>Educational objective:</strong><br>Cytochrome P450 enzymes found in the liver are responsible for the majority of drug metabolism.&nbsp; Polymorphisms occurring in the genes coding for these enzymes result in various phenotypes that differ in their rates of metabolism; individual differences in phenotype alter treatment efficacy and drug toxicity.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1711",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 16-year-old girl is brought to the emergency department because of progressively increasing nausea, vomiting and right upper quadrant pain.&nbsp; She was initially seen in the emergency department 24 hours ago for nausea and vomiting but was discharged when her examination and laboratory studies were unremarkable.&nbsp; At today&#39;s visit, the patient reveals, &#x22;I am so upset.&nbsp; My boyfriend broke up with me and I have been taking a lot of pain medication to relieve my pain.&#x22;&nbsp; Temperature is 37.1 C (98.8 F), blood pressure is 108/70 mm Hg, pulse is 102/min, and respirations are 16/min.&nbsp; Pulse oximetry is 98% on room air.&nbsp; On examination, scleral icterus and marked right upper quadrant tenderness are present.&nbsp; Pupils are normal in size and reactive to light.&nbsp; Neurologic examination shows no abnormalities.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Total bilirubin</td><td>1.3 mg/dL</td></tr><tr><td>Alkaline phosphatase</td><td>120 U/L</td></tr><tr><td>Aspartate aminotransferase (SGOT)</td><td>3,906 U/L</td></tr><tr><td>Alanine aminotransferase (SGPT)</td><td>4,014 U/L</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following is the most likely underlying mechanism of drug toxicity in this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Cytotoxic T-cell response to hepatocyte proteins"
        },
        {
          "id": 2,
          "text": "Drug-mediated inhibition of bile flow"
        },
        {
          "id": 3,
          "text": "Drug metabolite&ndash;induced mitochondrial dysfunction"
        },
        {
          "id": 4,
          "text": "Drug&ndash;induced disruption of fatty acid metabolism"
        },
        {
          "id": 5,
          "text": "Reactive oxygen species&ndash;induced stellate cell activation"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Acetaminophen poisoning</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t71535\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Acetaminophen overdose</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathophysiology</strong></p></td><td><ul><li>Depletion of intrahepatic glutathione &rarr; overaccumulation of NAPQI</li><li>NAPQI forms adduct with mitochondrial proteins &rarr; oxidative hepatocellular injury</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Initially asymptomatic or nonspecific (eg, nausea, vomiting, malaise)</li><li>Can progress to right upper quadrant pain, jaundice, hepatic encephalopathy &amp; bleeding diathesis</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory findings</strong></p></td><td><ul><li>Normal until 24 hr after ingestion</li><li>&uarr;&uarr; AST, ALT (often &gt;1,000 U/L)</li><li>&uarr; PT, PTT when severe</li><li>&plusmn; Elevated bilirubin &amp; alkaline phosphatase</li><li>Liver biopsy: centrilobular necrosis</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>N-acetylcysteine: replenishes intrahepatic glutathione stores</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>ALT</strong> = alanine aminotransferase; <strong>AST</strong><strong>=</strong> aspartate aminotransferase; <strong>NAPQI</strong> = N-acetyl-p-benzoquinone imine.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient who took large quantities of a pain medication initially had nausea and vomiting and has now developed scleral icterus, right upper quadrant pain, and markedly elevated aminotransferases.&nbsp; These findings are consistent with an overdose of <strong>acetaminophen</strong>, a commonly used analgesic.</p><p>When taken at appropriate doses, acetaminophen produces small amounts of the <strong>toxic metabolite</strong> <a href=\"45689\">N-acetyl-p-benzoquinone imine (NAPQI)</a>, which is conjugated with glutathione in the liver and excreted.&nbsp; At supratherapeutic doses, glutathione becomes saturated, allowing excessive amounts of NAPQI to form adducts with hepatic proteins that <strong>disrupt hepatocyte mitochondrial function</strong> and cause <strong>oxidative injury</strong>.</p><p>Because acetaminophen-induced liver injury primarily affects hepatocytes (ie, <strong>hepatocellular liver injury</strong>), laboratory findings show markedly <strong>elevated aminotransferases</strong> with levels sometimes &gt;1,000 U/L.&nbsp; Mild elevations of bilirubin and alkaline phosphatase can be seen but may be normal.&nbsp; Liver biopsy shows centrilobular hepatic necrosis, a common finding in ischemic or toxic liver injury.</p><p><strong>(Choice A)</strong>&nbsp; Certain drugs (eg, carbamazepine, phenytoin) can trigger a robust CD4<font size=\"2\"><sup>+</sup></font> and CD8<font size=\"2\"><sup>+</sup></font> T-cell response against hepatic proteins, leading to drug reaction with eosinophilia and systemic symptoms (DRESS).&nbsp; Although hepatocellular liver injury can occur, fever, lymphadenopathy, and skin manifestations (eg, facial edema, coalescing erythema) would be expected.</p><p><strong>(Choice B)</strong>&nbsp; Drug-mediated (eg, ceftriaxone) cholestatic liver injury typically causes biliary duct damage or interrupts the flow of bile.&nbsp; These patients have markedly elevated levels of alkaline phosphatase (and sometimes bilirubin), and aminotransferase levels are typically normal.</p><p><strong>(Choice D)</strong>&nbsp; Microvesicular steatohepatitis, or small droplets of intracytoplasmic lipids within hepatocytes, is caused by drugs that disrupt fatty acid beta-oxidation.&nbsp; Ibuprofen and aspirin are commonly used analgesics that can rarely lead to this condition; however, marked aminotransferase elevations are not seen in ibuprofen toxicity, and aspirin toxicity is usually seen in young children with a recent viral infection (ie, Reye syndrome).</p><p><strong>(Choice E)</strong>&nbsp; Chronic alcohol consumption can generate reactive oxygen species (ROS), which activate stellate cells and cause cirrhosis.&nbsp; Although NAPQI does create ROS, stellate cell activation does not occur, and this patient&#39;s acute liver injury after analgesic ingestion makes this diagnosis unlikely.</p><p><strong>Educational objective:</strong><br>Excessive acetaminophen use causes toxicity through its metabolite N-acetyl-p-benzoquinone imine, which disrupts hepatocyte mitochondrial function and induces oxidative injury throughout the liver.&nbsp; The resulting hepatocellular liver injury markedly elevates aminotransferase, with levels sometimes exceeding 1,000 U/L.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "19948",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 57-year-old man comes to the emergency department due to fevers and painful mouth ulcers.&nbsp; He recently began methotrexate therapy for psoriasis.&nbsp; However, the patient has mistakenly taken the medication daily instead of 3 times a week.&nbsp; His past medical history is also significant for hypertension and chronic kidney disease.&nbsp; Temperature is 38.1 C (100.6 F).&nbsp; Examination reveals multiple aphthous ulcers in the oral pharynx.&nbsp; A complete blood cell count is as follows:</p><blockquote><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Hemoglobin</td><td>10.4 g/dL</td></tr><tr><td>Platelets</td><td>120,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>Leukocytes</td><td>2,800/mm<font size=\"2\"><sup>3</sup></font></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></blockquote><p>Which of the following is the best next step in management?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Allopurinol"
        },
        {
          "id": 2,
          "text": "Amifostine"
        },
        {
          "id": 3,
          "text": "Dexrazoxane"
        },
        {
          "id": 4,
          "text": "Filgrastim"
        },
        {
          "id": 5,
          "text": "Folinic acid"
        },
        {
          "id": 6,
          "text": "Mesna"
        },
        {
          "id": 7,
          "text": "Ondansetron"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Methotrexate</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"2902\"  src=\"https://www.uworld.com/media/L25906.png\" draggable=\"false\" ></p><p><strong>Methotrexate</strong> (MTX) is a folic acid analog that <strong>inhibits dihydrofolate reductase</strong> (DHFR), the enzyme that converts dietary folic acid to tetrahydrofolate (THF), through direct competition.&nbsp; THF is a single-carbon group donor in the synthesis of purines and thymidylic acid (which contributes to pyrimidine formation).&nbsp; MTX functions as a chemotherapeutic agent through <strong>inhibition of DNA synthesis</strong> and as an anti-psoriasis agent through immunomodulatory effects on activated T cells.&nbsp; However, MTX causes death of all <strong>rapidly dividing</strong> cells, particularly those of the <strong>gastrointestinal tract</strong> (GI) mucosa (explaining this patient&#39;s <strong>aphthous ulcers</strong>) and <strong>bone marrow</strong> (explaining this patient&#39;s <strong>pancytopenia</strong>).</p><p><strong>Folinic acid (leucovorin)</strong> can reverse MTX toxicity if given early.&nbsp; It serves as a reduced form of folic acid thought <strong>not</strong> to require DHFR to be converted to THF and is therefore unaffected by MTX.&nbsp; Leucovorin is administered following high-dose MTX as part of a chemotherapeutic plan in which it serves to <strong>rescue</strong> bone marrow, and GI and other mucosal cells from MTX toxicity.&nbsp; In addition, when used in combination with 5-fluorouracil (<strong>5-FU</strong>), leucovorin <strong>potentiates</strong> the cytotoxic action of 5-FU (by binding thymidylate synthetase) and is frequently included in colorectal cancer chemotherapy regimens.</p><p><strong>(Choice A)</strong>&nbsp; Allopurinol and its metabolite, oxipurinol, are predominantly noncompetitive inhibitors of xanthine oxidase.&nbsp; Allopurinol is used in the treatment of gout and for prevention of tumor lysis syndrome.</p><p><strong>(Choice B)</strong>&nbsp; Amifostine is a cytoprotective free-radical scavenger used to decrease nephrotoxicity associated with platinum-containing and alkylating chemotherapeutic agents and to decrease xerostomia (dry mouth).</p><p><strong>(Choice C)</strong>&nbsp; Dexrazoxane is an iron-chelating agent that can prevent anthracycline-induced cardiotoxicity.</p><p><strong>(Choice D)</strong>&nbsp; Filgrastim is a granulocyte colony-stimulating factor analog used to stimulate the proliferation and differentiation of granulocytes in patients with neutropenia.</p><p><strong>(Choice F)</strong>&nbsp; Mesna prevents hemorrhagic cystitis due to cyclophosphamide or ifosfamide.&nbsp; Mesna binds acrolein, the toxic metabolite formed by these agents.</p><p><strong>(Choice G)</strong>&nbsp; Ondansetron (a serotonin 5-HT<font size=\"2\"><sub>3</sub></font> receptor inhibitor) is used to treat nausea and vomiting following chemotherapy.</p><p><strong>Educational objective:</strong><br>Folinic acid (leucovorin) can reverse the toxicity of methotrexate in non-cancerous cells in the gastrointestinal mucosa and bone marrow if administered at the appropriate time.&nbsp; Leucovorin serves as a reduced form of folic acid that does not require the action of dihydrofolate reductase.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1818",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A large, multinational drug corporation conducts a phase I clinical trial to evaluate the safety profile and pharmacokinetic properties of a new drug designed to treat refractory epilepsy.&nbsp; Initial studies in animals showed that the drug undergoes extensive metabolism by the liver into glucuronidation byproducts that are primarily excreted by the kidneys.&nbsp; The curve below demonstrates the glucuronidation rate of the drug over a wide range of doses.</p><p><img id=\"4960\"  src=\"https://www.uworld.com/media/L23999.jpg\"  draggable=\"false\" ></p><p>Which of the following is the most accurate statement about this drug&#39;s metabolism?</p>",
      "choices": [
        {
          "id": 1,
          "text": "A constant proportion of the drug is metabolized past point 3"
        },
        {
          "id": 2,
          "text": "Bioavailability of the drug is highest at point 1"
        },
        {
          "id": 3,
          "text": "Biotransformation of the drug ceases near point 2"
        },
        {
          "id": 4,
          "text": "Metabolism begins to switch to zero-order kinetics near point 2"
        },
        {
          "id": 5,
          "text": "The rate of drug metabolism is not dependent on dose before point 1"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Drug metabolism and clearance</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"4961\"  src=\"https://www.uworld.com/media/L24022.jpg\"  draggable=\"false\" ></p><p>The drug under investigation is glucuronated by the liver into water-soluble byproducts that can then be excreted by the kidney.&nbsp; The graph above shows how the <strong>rate of drug glucuronidation</strong> changes with increasing drug doses.&nbsp; At lower doses, the quantity of drug-glucuronide formed is directly proportional to the dose administered (ie, as more of the drug is administered, more drug-glucuronide is produced).&nbsp; Because a <strong>fixed proportion</strong> of drug is converted to the metabolite, this early portion of the graph represents <strong>first-order kinetics</strong>.</p><p>As the active sites on glucuronosyltransferase become saturated, the drug-glucuronide rate does not continue to rise with increasing doses of the substrate drug.&nbsp; At this point (2 on the graph), the kinetics change from first- to <strong>zero-order kinetics</strong> and the graph levels out to a zero slope.&nbsp; With zero-order kinetics, <strong>a constant amount</strong> of drug is metabolized and eliminated per unit of time regardless of its concentration or dose.</p><p>Zero- and first-order kinetics can also be represented graphically by showing the decrease in <a href=\"2492\">drug concentration over time</a> after a single dose.&nbsp; Zero-order metabolism is indicated by a straight line with negative slope (fixed amount eliminated per unit of time), whereas first-order kinetics manifest as an exponential decay curve (fixed proportion eliminated per unit of time).</p><p><strong>(Choice A)</strong>&nbsp; After point 3, the curve remains flat, indicating that a constant amount of drug is metabolized per unit of time regardless of the dose.&nbsp; As higher doses are administered, the proportion that is converted to the metabolite becomes smaller (ie, the proportion metabolized is non-constant after point 3).</p><p><strong>(Choice B)</strong>&nbsp; Bioavailability is the fraction of an administered drug that reaches the systemic circulation unchanged.&nbsp; It usually decreases with oral administration due to incomplete absorption and first-pass metabolism compared to parenteral administration.&nbsp; In this case, higher doses of the drug are likely to have greater bioavailability due to the saturation of hepatic metabolism.</p><p><strong>(Choice C)</strong>&nbsp; At point 2, biotransformation (ie, metabolism) of the drug begins to switch from first-order to zero-order kinetics due to enzyme saturation.&nbsp; However, drug metabolism does not stop.</p><p><strong>(Choice E)</strong>&nbsp; Before point 1, drug metabolism proceeds via first-order kinetics.&nbsp; Therefore, the drug metabolization rate increases as higher doses are administered.</p><p><strong>Educational objective:</strong><br>In first-order kinetics, a constant fraction (or proportion) of drug is metabolized per unit of time, so the amount metabolized changes based on the serum concentration.&nbsp; In zero-order kinetics, a constant amount of drug is metabolized per unit of time, independent of serum levels.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1716",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 55-year-old woman is diagnosed with metastatic breast cancer.&nbsp; The patient is treated with an opioid analgesic for bone pain that is well controlled during the first week of therapy.&nbsp; The following week, the analgesic dose becomes ineffective and the patient reports nausea, itching, and constipation.&nbsp; She has become very weak and is unable to walk due to the pain.&nbsp; The opioid dose is increased.&nbsp; The patient is concerned about side effects with higher dosages, noting that her son has a history of opioid dependence, and &#x22;I watched him suffer a lot of bad reactions.&#x22;&nbsp; The physician explains the concept of tolerance to opioids and that high doses are commonly required to control pain.&nbsp; Over the next few weeks, the patient would likely experience which of the following?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Euphoria"
        },
        {
          "id": 2,
          "text": "Increased itching"
        },
        {
          "id": 3,
          "text": "Persistent nausea and vomiting"
        },
        {
          "id": 4,
          "text": "Respiratory depression"
        },
        {
          "id": 5,
          "text": "Sedation"
        },
        {
          "id": 6,
          "text": "Urinary retention"
        },
        {
          "id": 7,
          "text": "Worsening constipation"
        }
      ],
      "correct_choice_id": 7,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Pharmacology (General Principles) > Opioids</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Opioid therapy is the first-line treatment for chronic cancer pain, with effective management commonly requiring higher doses over prolonged periods.&nbsp; An increase in dosage is often necessary to maintain adequate pain control following the development of tolerance to analgesic effects.&nbsp; Tolerance to most opioid side effects is also expected to occur.&nbsp; However, tolerance to constipation and miosis does not readily occur, and <strong>constipation</strong> is the most <strong>common</strong> and <strong>persistent opioid side effect</strong>.</p><p>Opioids stimulate mu receptors in the gastrointestinal tract, causing decreased secretions and gastric motility.&nbsp; Normal bowel function rarely resumes.&nbsp; Patients who require prolonged opioid therapy should receive a <strong>prophylactic bowel regimen</strong> (increased fluid intake, dietary fiber, and laxatives) to minimize constipation.</p><p><strong>(Choice A)</strong>&nbsp; Opioids can produce significant euphoria, mood alterations, and rewarding pleasurable effects.&nbsp; The mechanism of euphoria and rewarding properties may involve dopaminergic pathways in the nucleus accumbens.&nbsp; Tolerance to euphoric effects develops rapidly, underlying the addictive potential of this medication class.</p><p><strong>(Choice B)</strong>&nbsp; In most cases, opioid-induced pruritus is mild and tolerance develops.</p><p><strong>(Choice C)</strong>&nbsp; Nausea with or without vomiting is a common side effect during initiation of opioid therapy, but tolerance develops within days and persistent nausea is uncommon.&nbsp; Opioids stimulate the chemoreceptor trigger zone, leading to emesis.</p><p><strong>(Choice D)</strong>&nbsp; Respiratory depression is the most serious, yet rare, side effect of opioid therapy.&nbsp; Opioids depress respiration by reducing responsiveness of brainstem respiratory centers to increased levels of carbon dioxide.&nbsp; Patients who take opioids regularly are unlikely to develop respiratory depression as tolerance to this side effect develops rapidly.</p><p><strong>(Choice E)</strong>&nbsp; Sedation typically occurs during initiation of therapy and usually disappears after several days.&nbsp; It is not unusual for patients to be drowsy and sleep more during the first days of therapy.</p><p><strong>(Choice F)</strong>&nbsp; Opioids block urinary voiding reflexes and also increase sphincter tone and bladder volume.&nbsp; This results in an antidiuretic effect and urinary retention.&nbsp; Tolerance to these effects develops rapidly.</p><p><strong>Educational objective:</strong><br>Chronic opioid use leads to the development of tolerance to analgesic effects and most side effects, with the exception of constipation and miosis.&nbsp; To prevent bowel complications, it is recommended that patients be treated prophylactically with adequate fluid intake and daily laxatives.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1257",
      "difficulty": "N/A"
    }
  ]
}